UNSPSC 51111732: Bisantrene

This classification denotes an anthraquinone compound with the molecular formula C22H22N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39C34M111K, chemically known as 9,10-anthracenedicarboxaldehyde, bis((4,5-dihydro-1h-imidazol-2-yl)hydrazone)- but generally known as bisantrene, which bears US NIH Compound Identifier 5351322. Bisantrene most often comes in base, dihydrochloride, and hydrochloride forms.

UNSPSC 51111732 Bisantrene, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The four most recent opportunities posted under this code solicit naloxone and drug deactivation systems, medical and first aid supplies for fire rescue operations, generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle, and direct-to-manufacturer pharmacy program consultation—none of which involve bisantrene, a chemotherapy agent. The code's nominal scope and actual solicitation activity diverge substantially, indicating either a taxonomic mislabeling in the source records or opportunistic use of the code by procurement offices unfamiliar with UNSPSC hierarchy.

The recent activity shows issuing bodies across multiple government tiers: Seminole County, Florida (county health procurement); the City of Tampa (municipal fire services procurement); the Minnesota Multistate Cooperative Purchasing Alliance (state cooperative vehicle serving state and local members across multiple states including Oregon); and the Texas Health and Human Services Commission (state agency RFI). The geographic spread includes Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the City of Tampa's ITB 26P00145 for medical and first aid supplies (estimated $700,000) with a March 13, 2026 deadline, sheltered for certified Small Local Business Enterprises with a 5 percent bid discount capped at $10,000; the Minnesota Multistate Cooperative's RFP S1070000015802 for generic pharmaceuticals and OTC products due March 26, 2026; and the Texas HHS RFI HHS0017013 posted April 3, 2026, exploring direct-to-manufacturer prescription programs. The code shows no relevant recent activity for bisantrene procurement.